SEQENS group’s values are :
- Entrepreneurship
- Unity
- Customer focus
- Tenacity
- Agility & reactivty
About us
OUR MISSION
CELLforCURE by SEQENS provides complete, customized solutions for the development and manufacturing of cell and gene therapies, supporting our partners in accelerating their projects.
Our History
2010-2018
Creation by LFB
- Opening of the GMP site at Les Ulis in 2014
- ANSM (French branch EMA) approval for C&G manufacturing in 2015
- GMP certificate in 2016
2018
Acquisition by Novartis
- Commercial production of autologous CAR-T cells
2023
Acquisition by SEQENS
- CELLforCURE by SEQENS: CDMO for clinical and Commercial Cell&Gene therapies
OUR CULTURE
CELLforCURE by SEQENS, our mindset and ways of working are guided by our customer satisfaction objective.
Our partnership and collaborative approach results from 10 years of real-life Cell and Gene experience.
SEQENS group’s values are :
SEQENS group’s values are :
Leadership Team
CELLforCURE by SEQENS Leadership Team
Pierre-Noël
Lirsac
President of CELLforCURE SAS and Chief Executive Officer
Hélène
Negre
Responsible Pharmacist and Pharmaceutical Affairs Director
Marc-Olivier
Mignon
Chief Commercial Officer
Najia
Glaserman
Project Director
Nathalie
Lelot
Chief Operating Officer
Aurélie
Kerveadou
Human Resources Director
Priscille
Queant
Environment, Health & Safety Manager
Scientific committee
CELLforCURE by SEQENS
Scientific Committee Members
Pascale
Bouillé
Cell and Gene Therapy consulting at LivyBio
Olivier
Danos
Executive Vice President and Chief Scientific Officer of REGENXBIO Inc.
Annelise
Bennaceur-Griscelli
Professor of Onco-Hematology at Paris Saclay University and Director of CiTHERA
Dr
Philippe
Menasché
Cardiac surgeon & Professor of Thoracic and Cardiovascular Surgery at the Université Paris-Cité
Sebastian
Amigorena
Director of the Center of Immunotherapy for cancers and the Immune responses and cancer Team at Institut Curie
Christian
Jorgensen
Professor and Director, IRMB and IHU Immun4cure at the Montpellier University Hospital